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Abstract

Human β-galactoside α-2,6-sialyltransferase I (hST6Gal I) catalyses the synthesis of sialylated glycoconjugates
involved in cell-cell interactions. Overexpression of hST6Gal I is observed in many different types of cancers,
where it promotes metastasis through altered cell surface sialylation. A wide range of sialyltransferase (ST)
inhibitors have been developed based on the natural donor, cytidine 5′-monophosphate N-acetylneuraminic
acid (CMP-Neu5Ac). Of these, analogues that are structurally similar to the transition state exhibit the
highest inhibitory activity. In order to design inhibitors that are readily accessible synthetically and with
favourable pharmacokinetic properties, an investigation of the replacement of the charged phosphodiesterlinker, present in many ST inhibitors, with a potential neutral isostere such as a carbamate or a 1,2,3-triazole
has been undertaken. To investigate this, molecular docking and molecular dynamics simulations were
performed. These simulations provided an insight into the binding mode of previously reported
phosphodiester-linked ST inhibitors and demonstrated that targeting the proposed sialyl acceptor site is a
viable option for producing selective inhibitors. The potential for a carbamate- or triazole-linker as an isosteric
replacement for the phosphodiester in transition-state analogue ST inhibitors was established using molecular
docking. Molecular dynamics simulations of carbamate- and phosphodiester-linked compounds revealed that
both classes exhibit consistent interactions with hST6Gal I. Overall, the results obtained from this study
provide a rationale for synthetic and biological evaluation of triazole- and carbamate-linked transition-state
analogue ST inhibitors as potential new antimetastatic agents.
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Abstract:
Human β-galactoside α-2,6-sialyltransferase I (hST6Gal I) catalyses the synthesis of
sialylated glycoconjugates involved in cell-cell interactions. Overexpression of hST6Gal I is
observed in many different types of cancers, where it promotes metastasis through altered cell
surface sialylation. A wide range of sialyltransferase (ST) inhibitors have been developed
based on the natural donor, cytidine 5’-monophosphate N-acetylneuraminic acid (CMPNeu5Ac). Of these, analogues that are structurally similar to the transition state exhibit the
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highest inhibitory activity. In order to design inhibitors that are readily accessible
synthetically and with favourable pharmacokinetic properties, an investigation of the
replacement of the charged phosphodiester-linker, present in many ST inhibitors, with a
potential neutral isostere such as a carbamate or a 1,2,3-triazole has been undertaken. To
investigate this, molecular docking and molecular dynamics simulations were performed.
These simulations provided an insight into the binding mode of previously reported
phosphodiester-linked ST inhibitors and demonstrated that targeting the proposed sialyl
acceptor site is a viable option for producing selective inhibitors. The potential for a
carbamate- or triazole-linker as an isosteric replacement for the phosphodiester in transitionstate analogue ST inhibitors was established using molecular docking. Molecular dynamics
simulations of carbamate- and phosphodiester-linked compounds revealed that both classes
exhibit consistent interactions with hST6Gal I. Overall, the results obtained from this study
provide a rationale for synthetic and biological evaluation of triazole- and carbamate-linked
transition-state analogue ST inhibitors as potential new antimetastatic agents.
Keywords: sialyltransferase; inhibitors; molecular docking; molecular dynamics simulations;
transition-state analogues; metastasis
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INTRODUCTION
Sialyltransferases (STs) are enzymes of the glycosyltransferase (GT) family that play an
integral role in the biosynthesis of sialic acid (N-acetylneuraminic acid, Neu5Ac) containing
oligosaccharides and glycoconjugates (Harduin-Lepers et al. 2001; Li and Chen 2012). STs
are anchored within the Golgi apparatus’ membrane, with a catalytic domain present in the
lumen (Figure 1; Li and Chen 2012). Generally in glycosylation reactions catalysed by STs,
the sugar nucleotide donor is cytidine 5’-monophosphate Neu5Ac (CMP-Neu5Ac) and the
acceptor is an oligosaccharide or glycoconjugate terminated by a galactose (Gal), Nacetylgalactosamine (GalNAc), or other sialic acid residue (Chen and Varki 2010; Li and
Chen 2012). STs are classified based on the position of the glycosyl acceptor that sialic acid
is transferred. In humans these are ST3, ST6 and ST8, which form an α-glycosidic bond
between the C2 atom of sialic acid and the 3’-, 6’- or 8’-hydroxyl group of the acceptor,
respectively (Harduin-Lepers et al. 2001; Wang 2005; Li and Chen 2012).
The focus of this work, β-galactoside α-2,6-sialyltransferase I (ST6Gal I), is one of the two
subfamilies of the ST6 family, that catalyse the transfer of a Neu5Ac residue to the 6’hydroxyl group of the terminal Gal residues of the disaccharide Galβ[1,4]GalNAc. This
disaccharide can be found free or as a terminal N-acetyllactosamine unit of N- or O- linked
oligosaccharides (Harduin-Lepers et al. 2001; Audry et al. 2011). Human ST6Gal I
(hST6Gal I; Figure 1) belongs to the GT29 family of GTs, which is comprised of eukaryotic
and viral STs (http://www.cazy.org; Lombard et al. 2014).
The first sequence data of ST6Gal I was determined from a cDNA clone from rats in 1987
(Weinstein et al. 1987), with the sequence of hST6Gal I described three years later
(Grundmann et al. 1990). The primary sequence of hST6Gal I, like all other eukaryotic STs,
contains four characteristic regions: a short N-terminal cytoplasmic domain, followed by a
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transmembrane domain that extends to a stem region and a larger C-terminal catalytic domain
that faces the lumen of the Golgi apparatus (Figure 1; Kuhn et al. 2013). Within the catalytic
domain there are four regions that show significant sequence conservation across eukaryotic
STs (Figure 1), known as sialyl motifs L, S, III and VS (Jeanneau et al. 2004). Residues of
motifs L (Trp181–Gly224; hST6Gal I numbering) and III (Tyr354–Gln357) are involved in
binding the donor substrate (Datta et al. 2001); motif S residues (Pro321-Phe343) are
involved in both donor and acceptor binding, while motif VS residues (His370–Glu375)
participate in the catalytic reaction (Datta 2009). The first 80 residues of hST6Gal I,
comprising the cytoplasmic domain, transmembrane domain and stem region, can be deleted
without affecting activity (Legaigneur et al. 2001; Datta 2009).
There were two decades between the identification of the primary sequence and reporting of
structural data of mammalian ST6Gal I, with ligand conformation and protein-ligand contact
surfaces identified using nuclear magnetic resonance (NMR) appearing in 2007 and 2009
(Liu et al. 2007; Liu et al. 2009). The first mammalian ST crystal structure published was that
of porcine ST3Gal I (Rao et al. 2009) in 2009, while the first mammalian ST6Gal I crystal
structures that came from rat (Meng et al. 2013) and human (Protein Data Bank (PDB) id:
4JS1, 4JS2; Kuhn et al. 2013) were published in 2013. In addition to these, crystal structures
of human ST8Sia III were published in 2015 (Volkers et al. 2015). All of the mammalian
structures published are of the soluble catalytic domains with the cytoplasmic domain,
transmembrane domain and a portion of the stem region deleted.
Human ST6Gal I adopts the GT-A (variant 2) fold, a seven-stranded central β-sheet flanked
by multiple α-helices, and exhibits three disulphide bonds Cys142-Cys406, Cys184-Cys335
and Cys353-Cys364. The hST6Gal I crystal structure revealed that CMP binds with the
ribose in a 3’-endo conformation created via interactions with the first and last residues of a
SerSerGly sequence within the sialyl motif S (Figure S1). The disulphide bond Cys3534

Cys364 is contained within a well-defined loop, packing on top of the nucleoside. The glycan
binding observed, showed the 6’-hydroxyl of the acceptor close to His370, a potential
catalytic residue (Kuhn et al. 2013). Mutation carried out upon the equivalent histidine
(His367) of rat ST6Gal I resulted in no detectable catalytic activity (Meng et al. 2013), which
supports the conclusion that His370 is a catalytic residue in hST6Gal I.
It has been proposed that the mechanism of ST6Gal I (Figure 2) proceeds via nucleophilic
attack on the Neu5Ac anomeric carbon by the deprotonated Gal 6’-hydroxyl of the
disaccharide Galβ[1,4]GalNAc acceptor, facilitated by the catalytic His370 (Breton et al.
2012; Meng et al. 2013). This generates an oxocarbenium-like transition state, with the CMP
portion acting as a leaving group. The β-configuration at the anomeric carbon of the donor is
inverted in the final product (Breton et al. 2012). These aspects suggest that ST6Gal I
functions as an inverting GT, utilising an SN2-like direct displacement mechanism (Lairson et
al. 2008; Audry et al. 2011). This is supported by a model of the Michaelis complex
generated from the glycan binding mode observed in the crystal structure of hST6Gal I (Kuhn
et al. 2013).
Depending on the substrate targeted by ST6Gal I, α-2,6-sialylation can modulate protein
conformation, oligomerisation and/or receptor internalisation (Schultz et al. 2013).
Overexpression of ST6Gal I is observed in many different types of cancers including lung,
cervical, ovarian, breast and colon carcinoma (Cerami et al. 2012; Schultz et al. 2013). It has
been suggested that the overexpression of ST6Gal I promotes cancer cell metastasis through
altered sialylation patterns affecting the function of β1 integrin (Seales et al. 2005; Shaikh et
al. 2008). ST6Gal I also has an important function in the regulation of galectins, via the
sialylation of their galactose-containing substrates (Schultz et al. 2012; Schultz et al. 2013).
For instance, α-2,6 sialylation of the galectin substrates, Fas and TNFR1 death receptors, has
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been shown to hinder the apoptosis process, thus identifying ST6Gal I overexpression as a
potential inhibitor of cell death pathways (Schultz et al. 2012; Schultz et al. 2013).
The overexpression of ST6Gal I in various cancers has lead to the hypothesis that it can serve
as a target for the development of new anti-cancer therapeutics. This has resulted in the
development of a diverse range of ST inhibitors (Drinnan et al. 2003; Jung et al. 2003; Wang
et al. 2003). Of these, analogues that are structurally similar to the proposed oxocarbenium
ion-like transition state (Figure 2) exhibit the highest affinity to STs (Schröder and Giannis
1999; Skropeta et al. 2004). Transition-state analogue inhibitors incorporating a 2-deoxy-2,3didehydro-N-acetylneuraminic acid (Neu5Ac2en) moiety are amongst the most potent
inhibitors, with the C2-C3 double bond mimicking the planar anomeric carbon of the
oxocarbenium transition state (Amann et al. 1998). An extra carbon between the anomeric
carbon and CMP leaving group oxygen was also incorporated to mimic the increased distance
between these two atoms in the transition state (Amann et al. 1998; Skropeta et al. 2004).
Derivatives with structural variations of the glycerol side chain of the Neu5Ac2en moiety
produced the greatest inhibitory activity. Of these, phenoxy derivative 1 (Figure 3, Ki =
29 nM), showed the greatest inhibition of rat liver α-2,6-ST and is one of the most potent
transition-state analogue ST inhibitors reported to date (Schwörer and Schmidt 2002).
Derivatives that incorporate an aryl replacement of the Neu5Ac2en moiety have comparable
activity to the phenoxy derivative 1 and are more synthetically accessible (Müller et al. 1998;
Schröder and Giannis 1999; Skropeta et al. 2004). Of these compounds the (R)-isomer of the
phenoxy derivative 2 was the most potent inhibitor of rat liver α-2,6-ST (Figure 3, Ki = 70
nM) and is used as the lead compound herein (Skropeta et al. 2004).
The charged phosphodiester linkage of transition-state analogue ST inhibitors, while
contributing to potency (Skropeta et al. 2003), is generally thought to introduce
pharmacokinetic issues such as: poor cellular permeability, low bioavailability and potential
6

loss of activity due to cleavage by phosphatases (Rye and Baell 2005; Kumar et al. 2013). In
this study, to produce potent ST inhibitors that are readily accessible and with favourable
pharmacokinetic properties, the replacement of the charged phosphodiester-linker of the lead
compound 2 with a neutral-linker, such as a rigid 1,2,3-triazole or a flexible carbamate has
been investigated. The 1,2,3-triazole motif is a suitable choice as it has previously been
shown to be an applicable phosphodiester isostere in transition-state analogue ST inhibitors
(Lee et al. 2006; Kumar et al. 2013), as well as being used as isosteres of pyrophosphatelinkers (Chen et al. 2010) and phosphodiester-linkers of oligonucleotides (El-Sagheer and
Brown 2010). To date, there are a paucity of examples of carbamates being used as isosteres
of phosphodiesters. Carbamates do, however, have potential to be an isosteric replacement, as
this group has similar hydrogen bonding capabilities to a phosphodiester group and will
maintain the three-atom distance between the cytidine moiety and Neu5Ac-mimic observed
in reported phosphodiester-linked ST inhibitors. To investigate the potential binding effects
of replacing the phosphodiester-linker in derivatives with triazoles (e.g. 3; Figure 3) and
carbamates (e.g. 4; Figure 3), molecular docking and molecular dynamics simulations with a
model of hST6Gal I were undertaken. Insight into this binding may suggest novel molecular
structures and design strategies for the future development of clinically-relevant and selective
ST inhibitors.
METHODS
Molecular docking setup: A selection of reported and newly designed inhibitors were
docked into the binding site of the hST6Gal I crystal structure (PDB id: 4JS2; Kuhn et al.
2013) and snapshots sampled from every 20 ns of MD simulations (see below) with
AutoDock Vina version 1.1.2. (Trott and Olson 2010). The structure of hST6Gal I was
prepared for docking with AutoDockTools 1.5.6 (ADT; Sanner 1999). The three-dimensional
structures of the inhibitors studied were prepared with ChemDraw 14.0 and Avogadro v1.1.1.
7

(Hanwell et al. 2012), with ADT used to assign both rigid and rotatable bonds and to remove
non-polar hydrogen atoms. PROPKA 3.1 (Søndergaard et al. 2011) was used to predict the
protonation state of active site residues and ionisable ligand groups at pH 7.0. Docking was
performed in a 30 Å × 30 Å × 30 Å box centred at the active site highlighted in the
hST6Gal I-CMP crystal structure (PDB id: 4JS2; Kuhn et al. 2013). The dimension was
chosen to ensure it was big enough to accommodate the largest ligands and their interacting
residues. In all the docking calculations, the receptor is kept rigid and no explicit waters have
been included. The docking procedure was validated by re-docking of CMP to replicate the
crystallographically determined hST6Gal I-CMP complex (Kuhn et al. 2013).
Molecular dynamics simulation setup: The crystal structure of hST6Gal I (PDB id: 4JS2)
was taken as the initial structure for the simulations and was prepared using VMD version
1.9.1. (Humphrey et al. 1996). An overview of all simulations is given in Table 1. Simulation
of the hST6Gal I-CMP complex, using the starting coordinates provided by the crystal
structure was undertaken to validate the molecular dynamics simulation protocols used. To
probe flexibility in the apo state, the hST6Gal I protein in the absence of a ligand was also
simulated. Simulation of hST6Gal I-inhibitor complexes with reported phosphodiester-linked
compounds 1 and 2 and the proposed carbamate-linked derivative (R)-4 (Figure 3) was
undertaken to determine if a carbamate-linker was a suitable replacement for the
phosphodiester-linker used in previously reported inhibitors of hST6Gal I. The initial
structure for the hST6Gal I-inhibitor complexes was taken from the docking studies detailed
above.
Preparation of each simulation involved solvating the system in a box of water molecules,
which extended approximately 9 Å from the surface of the protein. Each box was neutralised
with counter ions of Na+, with the salt (NaCl) concentration set to 0.15 mol/L. Simulations
were carried out using the NAMD 2.9 package (Phillips et al. 2005). The protein was
8

represented with the non-polarisable CHARMM PARAM36 force field (Brooks et al. 2009).
Each ligand if not represented in this force field, had a parameter and topology file generated
with the General Amber Force Fields (GAFF; Wang et al. 2004) using AmberTools13 (D.A.
Case et al. 2012). All of the systems were simulated in periodic boundary conditions using the
Langevin algorithm for maintaining the temperature at 298.15 K, and the Langevin Piston
Nose-Hoover method (Martyna et al. 1994; Feller et al. 1995) for keeping the pressure
constant at 1.0 bar. The electrostatic interactions were calculated using the Particle Mesh
Ewald method (Darden et al. 1993). The van der Waals forces were treated with a cut-off of
12 Å and a smoothening function between 10 and 12 Å. All of the covalent bonds involving
hydrogen were kept rigid with the RATTLE algorithm (Andersen 1983). The integration time
step was set to 1.0 fs, 2.0 fs and 4.0 fs for bonded, non-bonded and long range electrostatics
respectively. Equilibrium simulations for all systems were initially undertaken. During these
simulations a harmonic restraint was placed upon all Cα atoms of hST6Gal I, with a
decreasing force constant from 32.0 to 1.0 kcal/mol/Å2 over 10 ns. This decrease was
achieved gradually by halving the force constant for each respective 1 ns interval until a force
constant of 1.0 kcal/mol/Å2 was obtained (i.e. 32.0, 16.0 … 1.0 kcal/mol/Å2). A force
constant of 1.0 kcal/mol/Å2 was then applied for the remainder of the 10 ns thermal
equilibration. The simulations were further continued for 90 ns without any restraints. To
perform trajectory analysis snapshots were saved every picosecond (i.e. every 1000 steps).
Analysis: The docking protocols outlined above were validated by replication of the
experimentally determined binding mode of the mono-deprotonated CMP in the reported
hST6Gal I crystal structure (Figure S2; Kuhn et al. 2013). To assess the ability of AutoDock
Vina to rank potential hST6Gal I inhibitors in terms of their enzyme binding affinities,
focused docking of selected reported inhibitors into the active site of hST6Gal I was
undertaken.
9

To determine the optimal binding mode for each ligand investigated the top ranked models,
based on the scoring function for binding affinities in AutoDock Vina were examined in
VMD (Humphrey et al. 1996). Evaluation of the optimal binding mode was firstly based
upon comparison to the position of CMP component of the inhibitors investigated in relation
to residues that were highlighted as important for CMP binding in the crystal structure of
hST6Gal I (Kuhn et al. 2013). This was followed by comparison of the Neu5Ac mimic
position in relation to residues highlighted as interacting with the Neu5Ac component of
CMP-3-F-Neu5Ac in a model of the Michaelis complex generated for hST6Gal I (Kuhn et al.
2013). For each compound the arithmetic mean binding affinity of the optimal binding mode
was reported (Table 2-3). Two-tailed t-tests were used to determine whether differences in
the mean binding affinities were significant, with significance defined as P < 0.05 (Table S1S7).
To monitor the global properties of the structural evolution during MD simulations, atomic
positional root-mean-square deviations (RMSD) with respect to a reference structure and the
atomic positional root-mean-square fluctuations (RMSF) were calculated using VMD
(Humphrey et al. 1996).
Hydrogen bond interactions in the hST6Gal I-inhibitor complex simulations were analysed
according to a geometric criterion. A hydrogen bond was defined by a minimum
donor-hydrogen-acceptor angle of 120º and a maximum heavy atom distance of 3 Å.
Hydrophobic contacts were also analysed according to a geometric criterion of a maximum
distance of 4 Å between hydrophobic atom pairs. To identify these interactions CHARMM
version 38a1(Brooks et al. 2009) was utilised.
RESULTS AND DISCUSSION
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Structural flexibility of the apo and holo form of hST6Gal I: To assess the structural
stability and fluctuations of the recently reported hST6Gal I crystal structure (Kuhn et al.
2013) in both the apo and holo forms, MD simulations were performed. The Apo, CMP2 and
CMP3 simulation RMSDs for carbon alpha (Cα) converged at 1.5 Å with CMP1 converging
at 2.5 Å (Figure S3), indicating no significant change in the structure of the protein backbone.
It should be noted that during the CMP simulations the CMP ligand remained tightly
associated with the expected binding site. RMSFs for the Cα atoms, were comparable across
the Apo and three CMP simulations (Figure S4). Each simulation showed consistently larger
RMSF values for the flexible loop between Tyr355 and Tyr369.
Probing the interactions between reported inhibitors and hST6Gal I: Snapshots from the
Apo and CMP1 simulations were used to dock reported inhibitors (1-2 and 5-11, Table 2)
with similar results obtained with each condition. Results from CMP2 and CMP3 simulations
were not included as no significant difference in binding affinity or binding mode was
observed between the docking into the snapshots of each CMP simulation.
For both the Apo and CMP1 cases the AutoDock Vina scoring function for the more potent
inhibitors (1-2, 5-8) was unable to differentiate between compounds that exhibited similar Ki
values (Table 2). For the less potent inhibitors (9-11) the AutoDock Vina scoring function
was unable to differentiate between any of these compounds despite the large differences in
Ki observed experimentally (Table 2). This suggests that obtaining a perfect ranking of
docked compounds using this protocol is unlikely, which is consistent with the error reported
in the systematic benchmarking studies for AutoDock Vina (Trott and Olson 2010).
Encouragingly though, the scoring function was generally able to predict a significant
difference between inhibitors of nanomolar, submicromolar, micromolar and submillimolar
Ki (Table S1-S2), providing confidence that an indication of relative binding affinity between
compounds could be obtained. In addition, experimentally reported trends were also observed
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in the docking studies such as: no significant difference in binding affinity between the
Neu5Ac2en containing 1 and its more synthetically accessible counterpart 2 being observed
(Müller et al. 1998; Schröder and Giannis 1999; Skropeta et al. 2004); and a m-phenoxy
substituted inhibitor (e.g. 2) exhibiting greater binding affinity than the analogous
unsubstituted inhibitor (e.g. 6; Skropeta et al. 2004).
For all compounds except 1, the binding affinity results obtained from docking into the Apo
and CMP1 MD sampled structures were not significantly different (Table S3). However, in
terms of the positioning of the inhibitors, docking using the MD sampled structures of the
CMP1 simulation generally produced binding modes that were more consistent. This was
particularly evident in the docking into the 80 ns and 100 ns snapshots, where CMP1 docking
conditions produced binding modes where the CMP moiety of each inhibitor reflected the
interactions highlighted within the hST6Gal I crystal structure (Kuhn et al. 2013), which was
not consistently the case for the Apo docking conditions. This can be rationalised in that
during the Apo simulation hST6Gal I relaxed back to the apo form, from the starting
“induced-fit” form of the co-crystallised CMP-hST6Gal I structure.
Probing the interactions between 1,2,3-triazole- and carbamate-linked compounds and
hST6Gal I: Based on the results discussed above, docking of the triazole- (3, 12-22) and
carbamate-linked compounds (4, 23-33) was undertaken using MD snapshots from the CMP1
simulation (Table 3). Of the compounds docked there were six ((R)-3, (R)-4, 12, 16, 23 and
27) that only differed from the literature inhibitors examined by the replacement of the
phosphodiester-linker with either a triazole or carbamate. The mean binding affinities for all
analogous compounds, except for the phosphodiester-linked m-trifluoromethoxy (S)-5 and
the corresponding triazole (S)-12, were not significantly different (Table S4). For these
triazole- and carbamate-linked compounds the position within the active site (Figure 4A) was
also comparable to those obtained for their phosphodiester-linked counterparts, indicating
12

that these linkers may be feasible replacements of the reported phosphodiester-linker. This
docking study also shows generally no significant difference between analogous carbamateand triazole-linked compounds (Table S5). This suggests that in most cases there may be no
preference for either a flexible carbamate- or rigid triazole-linker as an isostere for the
phosphodiester-linker.
The triazole and carbamate compounds generally demonstrated no significant difference
between the (R) and (S)-configured diastereomers of the same compound (Table S6-S7),
consistent with earlier findings reported in the literature (Schwörer and Schmidt 2002;
Skropeta et al. 2004). This counterintuitive result observed both experimentally and in silico
appears to be related with the sufficient space available within the active site to accommodate
the different stereochemistry, whilst maintaining proximity to residues that are expected to be
key in binding of the inhibitors.
Different substituents upon the aryl portion of the triazole- and carbamate-linked compounds
were also examined (Table 3 and S5-S7). The use of methoxy (13 and 24) and propoxy (14
and 25) m-substituents resulted in comparable predicted binding affinity to the corresponding
unsubstituted triazole 16 and carbamate 27. However, the use of a phenoxy (3 and 4)
m-substituent exhibited a significant increase in predicted binding affinity when compared to
the analogous unsubstituted triazole 16 and carbamate 27, as observed experimentally for the
corresponding phosphodiester-linked compounds (Skropeta et al. 2004). The other
m-substituent examined was trifluoromethoxy. For both isomers of the m-trifluoromethoxy
carbamate 23 there was a significant increase in predicted binding affinity compared to the
corresponding unsubstituted carbamate 27. In contrast the (S)-configured diastereomer of
m-trifluoromethoxy triazole 12 had a significantly larger predicted binding affinity than the
corresponding unsubstituted triazole 16, which was not observed for the (R)-configured
diastereomer of 12. Comparing each of the m-substituents shows that for the carbamate13

linked inhibitors the m-phenoxy diastereomers (4) showed a significant increase in predicted
binding affinity compared to m-methoxy (24) and m-propoxy (25) diastereomers, whereas no
significant difference was observed for m-trifluoromethoxy diastereomers (23). These trends
were not observed for the triazole-linked inhibitors with the only the (R)-configured
diastereomer of the m-phenoxy triazole 3 shown to have significant improvement over the
(R)-configured diastereomer of m-propoxy triazole 14. The p-substituted methoxy triazole
(15) and carbamate (26) showed comparable binding with the non-substituted counterparts
(16 and 27 respectively). It should be noted that this method is providing an indication of
relative binding affinity between compounds and further exploration of substituents and
substituent patterns needs to be undertaken before any definite conclusions can be drawn.
Compounds where a hydroxyl, methyl carbonate and methyl sulphonamide were trialled at
the position of the phosphonate group of 16 and 27, were also examined (Table 3 and S5-S7).
For both the triazole (17-19) and carbamate (28-30) examples, no significant difference was
observed between these compounds and the corresponding phosphodiester compounds,
suggesting that these groups may also be potential isosteres. Although it should be noted that
experimentally a charged group at this position, in particular a phosphonate, has been shown
to produce the most potent inhibitors (Amann et al. 1998). Not being able to replicate this
experimental trend can be attributed to the accuracy of the scoring function used in AutoDock
Vina (Trott and Olson 2010).
Derivatives that are structurally different to the m-phenoxy structure of the lead compound
(2) were also examined (Table 3 and S5-S7). For instance the triazole-linked indolone,
p-tolylsulphonamide and 2,3-dihydro-1H-indenol derivatives 20-22 produced docking results
that are comparable to the m-phenoxy structure 3. Interestingly, the corresponding carbamatelinked 31-33 did not exhibit the same trend, with only the (R)-configured diastereomer of the
indolone derivative 31, the (S)-configured diastereomer of the p-tolylsulphonamide 32 and
14

2,3-dihydro-1H-indenol derivatives 33 having comparable results to the m-phenoxy structure
4. This suggests that these structurally different derivatives benefit more from the rigidity
provided by a triazole-linker.
Key features of hST6Gal I-inhibitor complexes: The general binding mode observed for all
of the docked compounds exhibits a number of trends based on the different components of
these structures. The CMP moiety of each compound reflected the interactions highlighted
within the hST6Gal I crystal structure (Figure S1; Kuhn et al. 2013). The triazole- or
carbamate-linker were generally in the proximity of residues such as Asn212, Tyr354 and
His370, which is an analogous position to that observed for the phosphodiester-linker in
compounds 1-2 and 5-9. The groups that were mimicking the carboxylate of the natural
donor, such as a phosphonate, were shown to be positioned in proximity to a central α-helix
that has a positively polarised dipole (marked with an asterix in Figure 4A), that has been
proposed to interact with the carboxylate (Kuhn et al. 2013; Meng et al. 2013). The different
functionalities examined for the Neu5Ac mimic portion of the compounds were either located
within or oriented towards one of two binding pockets (Figure 4B), both of which could be
exploited in the future design of inhibitors of hST6Gal I. The first pocket, was occupied by
compounds such as the unsubstituted benzyls (16 and 27) and those bearing substituents such
as trifluoromethoxy (5, 12 and 23) or methoxy (13 and 24). This pocket is thought to be one
that the Neu5Ac of the sialyl donor could be accommodated within, based on the docking
results obtained for CMP-3-F-Neu5Ac (7) and CMP-Neu5Ac (8). In compounds bearing
larger substituents, such as a phenoxy (1-4) or a propoxy (14 and 25), these groups were
located within or oriented towards the predicted sialyl acceptor site. This provides a rationale
for the exploration of a potential route to selectivity, as each ST subfamily would be expected
to have differences in this region to accommodate the different sialyl acceptors.
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Molecular dynamics simulations of hST6Gal I-inhibitor complexes: To characterise
important binding interactions between hST6Gal I and potential inhibitors, four all-atom MD
simulations were performed in addition to those for CMP discussed previously. Two of these
simulations utilised the reported potent phosphodiester-linked (R)-isomers, 1 (PL1) and 2
(PL2). The remaining two simulations were of the analogous carbamate-linked (R)-4 (CAR1
and CAR2), with triazole-linked inhibitors to be examined in future studies. The PL1 and
PL2 simulation RMSDs for Cα converged at 1.5 Å, with CAR1 and CAR2 converging at
2.0 Å (Figure S5), indicating no significant change in the structure of the protein backbone. It
was noted that across all simulations each ligand remained tightly associated with the
hST6Gal I active site. RMSFs for the Cα atoms, were consistent across all simulations
(Figure S6). Each simulation showed consistently larger RMSF values for the flexible loop
between Tyr355 and Tyr369 and the region that lies between Gln235 and Asn250. This
region is adjacent to the portion of the active site that is expected to interact with the sialyl
acceptor and the large fluctuation is most likely a result of the phenoxy being within the
proposed sialyl acceptor site.
Interactions in the ligand-protein complexes analysed were characterised by monitoring the
hydrogen bonds and hydrophobic contacts (Table S8-S15). The simulations with CMP in
complex with hST6Gal I reproduced all hydrogen bonding interactions observed in the
crystal structure (Figure S1; Kuhn et al. 2013). Additional interactions observed include
Lys376 acting as a hydrogen bond donor to the pyridine like nitrogen of the cytosine ring and
Glu375 acting as a hydrogen bond acceptor to the 2’ hydroxyl group of the ribose. The water
molecules shown to interact with CMP in the crystal structure were not observed, with two
different bridging interactions from an oxygen of the phosphate group, to Ser189 and Tyr356
observed instead. Hydrophobic contacts that were observed were most significant with the
cytosine ring, which was shown to interact with Ala190 and also have a proposed π-stacking
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interaction with Tyr354. The ribose ring was shown to have hydrophobic interactions with
Ser189, Phe211 and Leu372.
The PL1, PL2 and CAR simulations each revealed a number of consistent hydrogen bond and
hydrophobic contacts with the hST6Gal I active site. These interactions have been
schematically illustrated in Figure 5. The respective compounds of each simulation were
shown to maintain the majority of the CMP moiety interactions that were observed in the
CMP simulations, with a notable absence of the proposed π-stacking of the cytosine ring with
Tyr354 in all cases. Additional water bridge interactions with the CMP moiety were also
observed, with the interaction between the free amine of the cytosine ring and the backbone
carbonyl of Val352 present in all simulations and the backbone NH of Gly324 and the 3’hydroxyl of the ribose observed in all simulations except CAR1.
As well as the CMP moiety, each compound examined had two other conserved regions, the
phosphonate and the m-phenoxy substituent. The conserved phosphonate component was
shown to hydrogen bond with Tyr354 in all simulations and Asn233 in all simulations except
PL2 (Figure 5). This does not correlate with the position generally observed in the docking
studies, suggesting another potential position for the phosphonate has been captured. The mphenoxy substituent for all compounds examined was shown to have hydrophobic contacts
with Asn233, Gln235, Trp257, Pro259, Tyr275 and Tyr369 (Figure 5), which are present in
the proposed sialyl acceptor binding site. This provides a further rationale for the exploration
of m-phenoxy type substituents to target the proposed sialyl acceptor binding site as a
potential route to the development of selective hST6Gal I inhibitors.
The two components of the compounds studied that were not consistent are the Neu5Ac
mimic and the linking group. The Neu5Ac mimic in the PL1 simulation, Neu5Ac2en was
shown to have limited interactions with hST6Gal I. Replacement of this moiety in the PL2
and CAR simulations with an aryl ring did not result in any significant change in interactions,
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which is consistent with the comparable activity of compounds 1 and 2 that has been
observed experimentally (Müller et al. 1998; Schröder and Giannis 1999; Skropeta et al.
2004). Consistent interactions were observed when comparing the phosphodiester-linker of
the inhibitors in the PL1 and PL2 simulations to the carbamate-linker in the CAR simulations
(Figure 5). These interactions include hydrogen bonding with Tyr354 and Asn212, which
were consistent across all simulations and water bridged interactions with Ser323 and His370
that were consistent across PL1 and CAR simulations. The similarity in interactions observed
for the carbamate-linker and the phosphodiester-linker in these simulations provides further
evidence that a carbamate-linker may be a suitable isosteric replacement for the
phosphodiester-linkers used in reported ST inhibitors.
Implication for inhibitor design: To further examine the promising trends that have been
observed in this study, more rigorous calculations of binding free energy beyond that of
molecular docking can be undertaken using techniques such as free energy perturbation
(Hansen and van Gunsteren 2014). Relative binding free energies between the different
linkers or different substitution patterns will provide insights into their effects on binding and
guide the experimental optimisation process. This work is currently undertaken in our lab and
will be reported in the future.
In previously published work, the utilisation of uncharged isosteres of phosphate in protein
tyrosine phosphatase inhibitors, has shown promising results for increasing cell permeability
and preventing cleavage by phosphatases (Rye and Baell 2005). Additionally, triazole-linkers
have been shown to be an applicable phosphodiester isostere in transition-state analogue ST
inhibitors (Lee et al. 2006; Kumar et al. 2013), suggesting that utilisation of uncharged
isosteres may be a suitable strategy for overcoming these pharmacokinetic concerns. Recent
work by Preidl et al. has demonstrated that derivatives of phosphodiester-linked transitionstate analogue ST inhibitors bearing a fluorescent probe are able to cross the cellular
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membrane via a vesicular uptake mechanism (Preidl et al. 2014), indicating that cell
permeability may not be an issue for these compounds. However, in vivo it is expected that
these phosphodiester-linked compounds would still be susceptible to phosphatase activity,
which can be overcome with a neutral isostere. As demonstrated in this study both triazole
and carbamate are potentially suitable isosteres for this purpose.
Improvements to the pharmacokinetic properties of transition-state analogue ST inhibitors
that could be gained by the introduction of a neutral triazole- or carbamate-linker could
logically be improved further by also replacing the charged phosphonate group with a neutral
isostere. However, for phosphodiester-linked transition-state analogues it has been
demonstrated experimentally that a charged group at this position, in particular a
phosphonate, produces the most potent inhibitors (Amann et al. 1998). In order to maintain
the phosphonate but still produce potential pharmacokinetic benefits, a neutral prodrug
approach could be undertaken. The use of phosphonate prodrugs has been shown to be
successful in producing several potent and selective nucleoside analogues that have clinical
applications in the human immunodeficiency virus (HIV), hepatitis B, and hepatitis C virus
fields (Pradere et al. 2014). A prodrug strategy as well as the incorporation of a neutral linker,
as described in this study, could produce improvements to the pharmacokinetic properties of
transition-state analogue ST inhibitors, and thus should be investigated further on a synthetic
and biological level.
CONCLUSIONS
Molecular docking and molecular dynamics simulations were performed to investigate the
replacement of the charged phosphodiester-linker used in reported transition-state analogue
ST inhibitors with a neutral isostere, such as a carbamate or a triazole. With the molecular
docking protocols used, eleven reported inhibitors and both the (R)- and (S)-configured
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diastereomers of twelve of each triazole- and carbamate-linked derivatives were examined.
This study successfully replicated experimental trends for reported inhibitors and furthermore
demonstrated the potential for both the use of a carbamate- or triazole-linker as an isosteric
replacement for the phosphodiester in transition-state analogue ST inhibitors. Molecular
dynamics simulations of four different ligands complexed with hST6Gal I were performed
and interactions in the complexes were characterised by monitoring hydrogen bonds and
hydrophobic contacts over the course of the simulation. This analysis replicated all the
hydrogen bonding interactions observed in the hST6Gal I-CMP complex crystal structure and
demonstrated that in a dynamic system the phenoxy substituent of compounds 1, 2 and (R)-4
are oriented towards the proposed sialyl acceptor site, encouraging the targeting of this site as
a potential route to design selective hST6Gal I inhibitors. Furthermore, it demonstrated that
the carbamate-linker of (R)-4 maintains the interactions with hST6Gal I observed for the
phosphodiester-linker in the simulations of the reported inhibitors 1 and 2. Overall, these
simulations provide not only a rationale for the synthetic and biological evaluation of 1,2,3triazole- and carbamate-linked transition-state analogue ST inhibitors, but also provide an
insight into binding of these compounds, which can aid in the design of future ST inhibitors.
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Table 1: Overview of all MD simulationsa
Name

Ligand

Apo
CMP1
CMP2
CMP3
PL1
PL2
CAR1
CAR2

cytidine 5’-monophosphate (CMP)
CMP
CMP
Phosphodiester-linked inhibitor 1
Phosphodiester-linked inhibitor 2
Carbamate-linked inhibitor (R)-4
Carbamate-linked inhibitor (R)-4

Total Simulation
Time (ns)
100
100
100
100
100
100
100
100

Equilibration (ns)
10
10
10
10
10
10
10
10

Free Simulation
(ns)
90
90
90
90
90
90
90
90

a

The systems consist of approximately 49 000 atoms with a box size of 81 Å × 81 Å × 81 Å
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Table 2: Mean binding affinitiesa of the optimal binding modes for reported ST inhibitors
based on AutoDock Vina
NH2
O
P O
R
O

N
N

O

O
OH OH

R

Cpd

Mean Binding

Mean Binding

b

c

Affinity Apo

Affinity CMP

Experimental

Experimental

rST6Gal I Ki (μM)

Estimate of Binding
Affinityd (kcal/mol)

(kcal/mol)

(kcal/mol)

(R)-1

-10.0 ± 0.2

-9.6 ± 0.1

0.029e

-10.3

(R)-2

-10.0 ± 0.2

-9.7 ± 0.2

0.070f

-9.8

(R)-5

-9.7 ± 0.1

-9.4 ± 0.2

0.25f

-9.1

(S)-5

-9.3 ± 0.2

-9.3 ± 0.2

0.22f

-9.1

(R)-6

-9.1 ± 0.2

-9.1 ± 0.1

0.20g

-9.2

P
OH

(S)-6

-8.9 ± 0.1

-8.8 ± 0.1

1.0g

-8.2

O

7

-8.4 ± 0.1

-8.5 ± 0.1

5.7h

-7.2

8

-8.6 ± 0.1

-8.6 ± 0.1

44i

-6.0

9

-8.2 ± 0.1

-7.9 ± 0.1

370j

-4.7

10

-8.0 ± 0.2

-7.8 ± 0.1

750i

-4.3

11

-8.2 ± 0.1

-7.9 ± 0.1

2000i

-3.7

O
H

O

O
AcHN

O P O
OH

HO

-

H O

OP
O
HO

O

F 3C
O
-

O

O
P
OH

O
O

-

HO

O

OH
OH
O

AcHN
HO

O
O

AcHN
HO

O
-

CO2

F

OH
OH

HO

-

O

CO2-

O

O
P
HO O-

-

O
O

a

Arithmetic mean binding affinity ± standard error of the mean (SEM) obtained from docking into six snapshots of MD
simulation.
b

Docking carried out on the snapshots from the Apo molecular dynamics simulations

c

Docking carried out on the snapshots from the CMP1 simulations.

d

Estimated using ∆𝐺 = 𝑅𝑅𝑅𝑅(𝐾𝑖 ) where R = 1.9872 x 10-3 kcal/K/mol, T = 300 K and Ki values were M

e
j

(Schwörer and Schmidt 2002); f (Skropeta et al. 2004);g (Müller et al. 1998); h (Burkart et al. 2000); i (Amann et al. 1998),
(Whalen et al. 2003)
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Table 3: Mean binding affinities of the optimal binding modes for 1,2,3-triazole- and carbamatelinked derivatives
NH2

NH2

N
N
R

R

Cpd

N

N

N

O

O
R

O
OH OH

Mean Binding Affinity

OP
O
HO

F 3C

-

O

O
P
OH

O

-

O

O
P
OH

O

O

P
-

O

O

OH

O

P
OH

Cpd

O

P
OH

OH

O
O
O

O
HN S
O

OH
O
N
H

O

Mean Binding Affinity
Carbamatea (kcal/mol)

-9.7 ± 0.1

(R)-4

-9.8 ± 0.2

(S)-3

-9.9 ± 0.1

(S)-4

-9.8 ± 0.2

(R)-12

-9.7 ± 0.2

(R)-23

-9.5 ± 0.1

(S)-12

-9.9 ± 0.1

(S)-23

-9.7 ± 0.2

(R)-13

-9.4 ± 0.2

(R)-24

-9.1 ± 0.2

(S)-13

-9.8 ± 0.2

(S)-24

-9.1 ± 0.2

(R)-14

-9.1 ± 0.1

(R)-25

-8.8 ± 0.1

(S)-14

-9.4 ± 0.2

(S)-25

-9.0 ± 0.2

(R)-15

-9.1 ± 0.2

(R)-26

-8.8 ± 0.1

(S)-15

-9.2 ± 0.2

(S)-26

-8.9 ± 0.1

(R)-16

-9.3 ± 0.1

(R)-27

-9.0 ± 0.2

(S)-16

-9.1 ± 0.2

(S)-27

-8.9 ± 0.1

(R)-17

-9.1 ± 0.2

(R)-28

-8.8 ± 0.1

(S)-17

-8.7 ± 0.1

(S)-28

-8.6 ± 0.2

(R)-18

-8.9 ± 0.2

(R)-29

-8.7 ± 0.2

(S)-18

-9.1 ± 0.2

(S)-29

-8.7 ± 0.2

(R)-19

-9.0 ± 0.1

(R)-30

-8.8 ± 0.1

(S)-19

-9.2 ± 0.1

(S)-30

-9.0 ± 0.1

(R)-20

-9.7 ± 0.1

(R)-31

-9.2 ± 0.3

(S)-20

-9.6 ± 0.2

(S)-31

-9.1 ± 0.1

O

-

N
O

(R)-3

O

-

N
H

OH OH

Triazolea (kcal/mol)
O

N

O
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O
HN S
O

OH

a

(R)-21

-9.8 ± 0.2

(R)-32

-9.1 ± 0.2

(S)-21

-10.0 ± 0.3

(S)-32

-9.6 ± 0.2

(R)-22

-9.7 ± 0.2

(R)-33

-9.1 ± 0.2

(S)-22

-9.5 ± 0.2

(S)-33

-9.2 ± 0.1

Arithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of CMP1 simulation.
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Figure Legends
Figure 1. The structure of hST6Gal I (PDB id 4JS2; Kuhn et al. 2013) with sialyl motifs
L (red), III (blue), S (yellow) and VS (orange) highlighted. The co-crystallised ligand
cytidine 5’-monophosphate (CMP) is represented as pipes. The soluble catalytic domain
of hST6Gal I extends into the lumen of the Golgi apparatus via a stem region from a
transmembrane domain and a short N-terminal cytoplasmic domain.
Figure 2. Proposed reaction scheme for the catalytic action of hST6Gal I. R represents a
glycan chain of a glycoconjugate.

Figure 3. Development of the phosphodiester-linked lead compound (2) and the proposed
1,2,3-triazole- (3) and carbamate- (4) linked derivatives. Reported Ki values expressed for
compounds 1 (Schwörer and Schmidt 2002) and 2 (Skropeta et al. 2004) are determined
against rat liver α-2,6-ST.
Figure 4. (A) Comparison of binding modes obtained using AutoDock Vina between the
phosphodiester-linked lead compound 2 (purple) and the 1,2,3-triazole- (R)-3 (green) and
carbamate-linked (R)-4 (orange) derivatives. Compounds pictured are the binding modes
obtained from docking into the 40ns snapshot of the CMP1 simulation. The backbone of
hST6Gal I is shown as grey ribbons and the central α-helix that has a positively polarised
dipole is marked with an asterix. (B) Surface model of hST6Gal I highlighting the two
possible
pockets
for the ofNeu5Ac
mimic
of the
proposed
inhibitors.
The
Figure 5.binding
Schematic
representation
conserved
hydrogen
bonding
(A) and
hydrophobic
compounds
shown
are
m-phenoxy
carbamate-linked
(S)-4
and
the
m-trifluoromethoxy
contacts (B) observed in the PL1, PL2 and CAR simulations. The consistent components
phosphodiester-linked
(R)-5 docked
into the
40ns snapshot
the represents
CMP1 simulation.
The
of each inhibitor are shown
as chemical
structures.
The redofbox
the different
predicted
accepter
site is circled
in blueNeu5Ac
with the
predicted
Neu5Ac
donor site
linkers andsialyl
the blue
box represents
the different
mimic.
Dashed
lines indicate
the
interacting atoms shown in Table S10-15 and “W” represents a single molecule of water.
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